1. Role: Director. Scope: Department. Date: 2019.
Grant H. Skrepnek, Ph.D., R.Ph.
Professor
Pharmacy Clinical & Admin Sci
Phone (405) 271-6878 x47105
Fax (4050 271-6430
Office CPB 214
Email grant-skrepnek@ouhsc.edu
Summary
I concentrate on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, I focus on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. I am engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.
Research
Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.
Publications & Presentations
- 36. Medina M, Schwier N C, Miller J L, Miller M M, Skrepnek G H. Career Skills Assessment in a Doctor of Pharmacy Curriculum. American journal of pharmaceutical education. 2018; 82 : 6300
37. Keast S, Holderread B, Cothran T, Skrepnek G H. Assessment of the effect of an enhanced prior authorization and management program in a United States Medicaid program on chronic hepatitis C treatment adherence and cost. Journal of the American Pharmacists Association : JAPhA. 2018; 58 : 485-491
38. Gentry C A, Giancola S, Kurdgelashvili G, Thind S, Skrepnek G H, Williams R J. A Propensity-Matched Analysis Between Standard Versus Tapered Oral Vancomycin Courses for the Management of Recurrent Clostridium difficile Infection. IDSA: Open Forum Infect Dis. 2017; 4 : 1-6
39. Skrepnek G H. Health Economics and Outcomes Research in Cancer. Springer. 2017
40. Miller J L, Lepa T M, Ranallo C, Chaaban H, Skrepnek G H, Johnson P N. Detectable Concentrations of Inhaled Tobramycin in Critically Ill Children Without Cystic Fibrosis: Should Routine Monitoring Be Recommended?. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2017; 18 : e615-e620
Grants
- 1. [Cooperative Agreement] Oklahoma State Department of Health, A Strategic Approach to Advancing Health Equity for Priority Populations with or at Risk for Diabetes – 2023 (DP-23-0020, FAIN #NU58DP007376, CFDA #93.988 (Cooperative Agreements for State-Based Diabetes Control Programs and Evaluation of Surveillance Systems). . CDC. Start Date: 2023. End Date: 2024.
2. [Cooperative Agreement] Oklahoma State Department of Health, Chronic Disease Prevention Program: The National Cardiovascular Health Program (DP-23-0004, FAIN #NU58DP007471, CFDA #93.426 - The National Cardiovascular Health Program, CDV/Heart. CDC. Start Date: 2023. End Date: 2024.
3. HIV Adherence Services. Start Date: 2022. End Date: 2023.
4. Patterns of Care, Outcomes, and Barriers to Treatment Success or Vaccination Associated with Adult Community-Acquired Pneumonia in Medicaid. Misc Non-Federal. Start Date: 2021. End Date: 2022.
5. [Service Agreement] Opioid Use Under Oklahoma Senate Bill 848.. Non-federal. Start Date: 2020. End Date: 2020.
Awards and Honors
no results
Education
no results
Administrative Assignments
2. Role: Director. Scope: Department. Description: Interim Director & Director of Academic Research. Date: 2019.